OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 90.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 125,589 shares of the company's stock after buying an additional 59,649 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.34% of iTeos Therapeutics worth $965,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Millennium Management LLC boosted its stake in shares of iTeos Therapeutics by 1,008.8% during the fourth quarter. Millennium Management LLC now owns 411,072 shares of the company's stock valued at $3,157,000 after acquiring an additional 373,999 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of iTeos Therapeutics by 347.9% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 922,134 shares of the company's stock worth $7,082,000 after purchasing an additional 716,271 shares during the period. Graham Capital Management L.P. purchased a new position in shares of iTeos Therapeutics during the fourth quarter valued at $85,000. Forefront Analytics LLC bought a new stake in shares of iTeos Therapeutics during the 4th quarter worth about $85,000. Finally, DAFNA Capital Management LLC lifted its position in shares of iTeos Therapeutics by 16.6% in the 4th quarter. DAFNA Capital Management LLC now owns 188,347 shares of the company's stock worth $1,447,000 after acquiring an additional 26,763 shares during the period. 97.16% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, major shareholder Ansbert Gadicke sold 1,031,931 shares of the business's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $8,317,363.86. Following the sale, the insider now directly owns 3,452,797 shares in the company, valued at approximately $27,829,543.82. The trade was a 23.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the business's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total value of $5,079,339.46. Following the transaction, the insider now directly owns 2,108,594 shares of the company's stock, valued at approximately $16,995,267.64. This represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 12.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Leerink Partners reiterated a "market perform" rating and issued a $9.00 price objective (down from $47.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Leerink Partnrs downgraded shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Wells Fargo & Company reiterated an "overweight" rating and set a $13.00 price target (down from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. HC Wainwright lowered iTeos Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, May 14th. Finally, Wedbush reiterated an "outperform" rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $17.86.

iTeos Therapeutics Trading Up 7.0%

iTeos Therapeutics stock traded up $0.55 during trading on Monday, reaching $8.36. The company had a trading volume of 835,077 shares, compared to its average volume of 547,966. iTeos Therapeutics, Inc. has a 52 week low of $4.80 and a 52 week high of $18.70. The firm's 50-day simple moving average is $6.61 and its 200 day simple moving average is $7.40. The firm has a market capitalization of $319.78 million, a price-to-earnings ratio of -2.63 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.14. On average, analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.